Paving the way for diversity in clinical trials
Hala Borno, MD, Assistant Professor of Medicine, Division of Oncology and Hematology, University of California, San Francisco
Jamie Freedman, head of U.S. medical affairs, Genentech.
Dr. Jennifer Jones-McMeans, Director of Global Clinical Problems at Abbott Pharmaceuticals.
Dr. Marya Shegog, Health Equity and Diversity Coordinator, Lazarex Cancer Foundation.
Mrs. Denicoff, registered nurse and nurse advisor, National Cancer Institute; head of clinical trial operations, NCI’s National Clinical Trials Network
‘Lola Fashoyin-Aje, MD, division director and associate director, science and policy for resolving differences, Center for Excellence in Oncology, FDA.
Keanna Ghazvini, spokeswoman, Pfizer Pharmaceuticals.
FDA: “Photos of Drug Tests: NINLARO.”
National Cancer Institute: “Inclusion of NIH policies and guidelines for women and minorities in clinical research”, “Participation in research involving women and minorities as human subjects”, “Cancer inequalities”.
Clinicaltrials.gov: “ClinicalTrials.gov Background.”
Lazarex Cancer Foundation.
Genentech Biotechnology Company.
Abbott Laboratories: “Abbott has announced the start of testing to evaluate the new scaffold for Espri Btk drug recovery.”
Association Against Cancer.
American Association of Clinical Oncology.
Current clinical trials: “Does the COVID-19 outbreak identify a broader need for urgent transformation in cancer clinical trial research?”
The New York Times: “Clinical trials are being taken out of the lab and into people’s homes.”
Massey Cancer Center, Virginia Commonwealth University: “First Lady Jill Biden visits Massey to study cancer inequality and community-based research.”
ProPublica: “Black patients lose drugs for hopeful cancers.”